Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults With Atopic Dermatitis

NCT04413942 is registered in ClinicalTrials.gov with Oneness Biotech Co., Ltd. as lead sponsor.

NCT NCT04413942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04413942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Multiple Intravenous Doses of FB825 in Adults With Atopic Dermatitis
Lead sponsor
Oneness Biotech Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
March 10, 2020
Completion date
June 30, 2022
Enrollment
99 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis